Clinical features and treatment status of systemic lupus erythematosus complicate with coronary heart disease
-
摘要: 系统性红斑狼疮（systemic lupus erythematosus，SLE）是一种累及多脏器的自身免疫性炎症性结缔组织病。近20年来，SLE全因病死率在不断下降，心血管疾病已成为SLE患者死亡最主要的原因。SLE合并冠心病（coronary hearty disease，CHD）是心血管事件主要表现形式，往往起病早、病变重、病死率高。积极控制危险因素、药物治疗和血运重建是降低其病死率的有效措施。Abstract: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory connective tissue disease involving multiple organs.In the past 20 years, the all-cause mortality of SLE has been decreasing continuously and cardiovascular diseases have become the most important cause of death.Among that, SLE complicate with coronary heart diseases (CHD) is a major form with an earlier onset, more severe coronary lesions, and high mortality rate.Active control of risk factors, drug therapy, and revascularization are effective treatments to reduce the mortality rate.
-
Key words:
- lupus erythematosus /
- systemic /
- atherosclerosis /
- coronary heart disease
-
-
[1] Fors Nieves CE, Izmirly PM.Mortality in systemic lupus erythematosus:an updated review[J].Curr Rheumatol Rep, 2016, 18(4):21.
[2] Croca S, Rahman A.Atherosclerosis in systemic lupus erythematosus[J].Best Pract Res Clin Rheumatol, 2017, 31(3):364-372.
[3] 蔡莉娜, 杨文博, 强红丽, 等.393例女性冠心病患者的临床特征及预后探讨[J].临床心血管病杂志, 2018, 34(9):876-879.
[4] 孟树萍, 胡延磊, 丁付燕, 等.冠状动脉病变与颈动脉粥样硬化及脑梗死的关系[J].临床心血管病杂志, 2018, 34(10):987-989.
[5] Tselios K, Urowitz MB.Cardiovascular and pulmonary manifestations of systemic lupus erythematosus[J].Curr Rheumatol Rev, 2017, 13(3):206-218.
[6] Bartels CM, Buhr KA, Goldberg JW, et al.Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort[J].J Rheumatol, 2014, 41(4):680-687.
[7] Avina-Zubieta JA, To F, Vostretsova K, et al.Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus:A general population-based study[J].Arthritis Care Res, 2017, 69(6):849-856.
[8] Wigren M, Nilsson J, Kaplan m J.Pathogenic immunity in systemic lupus erythematosus and atherosclerosis:common mechanisms and possible targets for intervention[J].J Int Med, 2015, 278(5):494-506.
[9] Ugarte A, Danza A, Ruiz-Irastorza G.Glucocorticoids and antimalarials in systemic lupus erythematosus:an update and future directions[J].Curr Opin Rheumatol, 2018, 30(5):482-489.
[10] Al Sawah S, Zhang X, Zhu B, et al.Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort[J].Lupus Sci Med, 2015, 2(1):e000066.
[11] Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al.Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus[J].Rheumatology, 2014, 53(8):1470-1476.
[12] Mok CC, Tse SM, Chan KL, et al.Effect of immunosuppressive therapies on survival of systemic lupus erythematosus:a propensity score analysis of a longitudinal cohort[J].Lupus, 2018, 27(5):722-727.
[13] Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al.Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control:An observational study[J].Arthritis Care Res (Hoboken), 2018, 70(4):582-591.
[14] Spinelli FR, Moscarelli E, Ceccarelli F, et al.Treating lupus patients with antimalarials:analysis of safety profile in a single-center cohort[J].Lupus, 2018, 27(10):1616-1623.
[15] Szabo MZ, Szodoray P, Kiss E.Dyslipidemia in systemic lupus erythematosus[J].Immunol Res, 2017, 65(2):543-550.
[16] Ulivieri C, Baldari CT.Statins:from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases[J].Pharmacol Res, 2014, 88:41-52.
[17] Jorge AM, Lu N, Keller SF, et al.The effect of statin use on mortality in systemic autoimmune rheumatic diseases[J].J Rheumatol, 2018, 45(12):1689-1695.
[18] Watanabe T, Oku K, Amengual O, et al.Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies[J].Lupus, 2018, 27(2):225-234.
[19] Yousef Yengej FA, Limper M, Leavis HL.Statins for prevention of cardiovascular disease in systemic lupus erythematosus[J].Neth J Med, 2017, 75(3):99-105.
[20] Iudici M, Fasano S, Gabriele Falcone L, et al.Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus:a long-term retrospective cohort study[J].Rheumatology, 2016, 55(9):1623-1630.
[21] Fasano S, Pierro L, Pantano I, et al.Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus[J].J Rheumatol, 2017, 44(7):1032-1038.
[22] Benvenuti F, Gatto M, Larosa M, et al.Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus:a literature review[J].Expert Opin Drug Saf, 2015, 14(9):1373-1385.
[23] Bundhun PK, Boodhoo KD, Long MY, et al.Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention:a systematic review and meta-analysis[J].Medicine (Baltimore), 2016, 95(12):e3200.
[24] Lai CH, Lai WW, Chiou MJ, et al.Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus:an 11-year nationwide cohort study[J].Ann Rheum Dis, 2016, 75(7):1350-1356.
[25] Lai CH, Lai WW, Chiou MJ, et al.Outcomes of coronary artery bypass grafting in patients with inflammatory rheumatic diseases:an 11-year nationwide cohort study[J].J Thorac Cardiovasc Surg, 2015, 149(3):859-866.
-
计量
- 文章访问数: 48
- PDF下载数: 23
- 施引文献: 0
下载: